Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CASI Pharmaceuticals (CASI) EBIT Margin (2022 - 2025)

Historic EBIT Margin for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to 266.47%.

  • Pharmaceuticals' EBIT Margin fell 455800.0% to 266.47% in Q2 2025 from the same period last year, while for Jun 2025 it was 276.14%, marking a year-over-year decrease of 1602700.0%. This contributed to the annual value of 138.84% for FY2024, which is 648100.0% down from last year.
  • Pharmaceuticals' EBIT Margin amounted to 266.47% in Q2 2025, which was down 455800.0% from 166.33% recorded in Q1 2025.
  • Over the past 5 years, Pharmaceuticals' EBIT Margin peaked at 49.85% during Q4 2023, and registered a low of 277.32% during Q1 2024.
  • In the last 4 years, Pharmaceuticals' EBIT Margin had a median value of 90.79% in 2023 and averaged 131.15%.
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -1909100bps in 2024, then soared by 1109900bps in 2025.
  • Over the past 4 years, Pharmaceuticals' EBIT Margin (Quarter) stood at 145.89% in 2022, then skyrocketed by 66bps to 49.85% in 2023, then plummeted by -343bps to 220.88% in 2024, then decreased by -21bps to 266.47% in 2025.
  • Its EBIT Margin was 266.47% in Q2 2025, compared to 166.33% in Q1 2025 and 220.88% in Q2 2024.